IN8bio
INAB
28 hedge funds and large institutions have $3.6M invested in IN8bio in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
17% more funds holding
Funds holding: 24 → 28 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.49% less ownership
Funds ownership: 1.38% → 0.89% (-0.49%)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
53% less capital invested
Capital invested by funds: $7.72M → $3.6M (-$4.12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$101K |
| 2 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
+$18.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.2K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$9.12K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.26M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$793K |
| 3 |
6CM
683 Capital Management
New York
|
-$193K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$90.6K |
| 5 |
Jane Street
New York
|
-$29.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SS
26
SBI Securities
Tokyo,
Japan
| $167 | +$271 | +34 | New |
|
27
Bank of America
Charlotte,
North Carolina
| $81 | +$8 | +1 | +7% |
|
28
JP Morgan Chase
New York
| $17 | -$8 | -1 | -25% |
|
|
6CM
29
683 Capital Management
New York
| – | -$193K | -25,000 | Closed |
|
|
30
Jane Street
New York
| – | -$29.8K | -3,864 | Closed |
|
31
Goldman Sachs
New York
| – | -$2.62K | -340 | Closed |
|
INAB Hedge Fund Activity: Q1 2025 in Review
28 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q1 2025, worth a combined $3.6M — down 53% from $7.72M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new INAB positions and 3 closed out — a net gain of 4 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $101K. The largest seller was AIGH Capital Management, cutting an estimated $1.26M.
- 28 institutional investors held IN8bio (INAB) as of Q1 2025, up from 24 in Q4 2024.
- Funds reported $3.6M of IN8bio stock for Q1 2025, down 53% quarter-over-quarter.
- 7 funds opened new IN8bio positions in Q1 2025 and 3 closed out, a net change of +4 holders.
- The largest IN8bio buyer in Q1 2025 was Vanguard Group, an estimated $101K added.
- The largest IN8bio seller in Q1 2025 was AIGH Capital Management, an estimated $1.26M sold.
Based on aggregated 13F filings for Q1 2025.